Recommend the map of innovation and development of China's pharmaceutical and health industry

China's pharmaceutical and health industry has initially formed an industrial cluster

First, innovative enterprises

First, innovative enterprises

The top 100 biomedical enterprises are concentrated in the Bohai Rim and yangtze River Delta regions

The top 100 biomedical enterprises are concentrated in the Bohai Rim and yangtze River Delta regions

Biomedical listed enterprises are concentrated in developed coastal provinces, forming a relatively long coastal distribution belt

Figure 1: Distribution of listed pharmaceutical and health enterprises nationwide as of July 31, 2022 Source: Flint Creation Industry Data Center

From the perspective of the segmentation of listed enterprises, listed biomedical companies are mainly concentrated in Beijing, Shanghai, Jiangsu, Guangdong and other regions

From the perspective of the new listed enterprises, from January 1, 2021 to July 31, 2022, there are 147 new listed pharmaceutical and health enterprises in China, focusing on the upstream nanosphere materials of medical devices, molecular diagnosis, POCT, immunodiagnosis, chemical drugs, antibody drugs, gene therapy, pharmaceutical outsourcing services, medical information services, and pharmaceutical business and other fields

Second, innovation capital

Second, innovation capital

Beijing, Shanghai, Guangdong, Jiangsu, Zhejiang and other five major provinces and cities lead more than 80% of China's total financing and activities in the field of medicine and health

Beijing, Shanghai, Guangdong, Jiangsu, Zhejiang and other five major provinces and cities lead more than 80% of China's total financing and activities in the field of medicine and health

From the perspective of the number of financing, since 2021, more than 2800 financing events have occurred in the biomedical field in China, and they are mainly concentrated in economically developed areas in

From the perspective of capital flow, it is mainly invested in the research and development of new tumor drugs, large molecule biological drug research and development, medical artificial intelligence, in vitro diagnosis, intelligent medical equipment, CRO, CDMO and other fields, and the influx of a large amount of funds has promoted the explosive growth

Figure 2: Distribution of financing amounts in China's pharmaceutical and health sector as of July 31, 2022 Source: Flint Creation Industry Data Center

M&A activities continue to be active, and the scale effect of head enterprises has begun to appear

M&A activities continue to be active, and the scale effect of head enterprises has begun to appear

Third, innovative achievements

Clinical trials of drugs in China are mainly concentrated in the eastern coastal areas and along the Yangtze River Economic Belt, and show obvious echelon characteristics

Clinical trials of drugs in China are mainly concentrated in the eastern coastal areas and along the Yangtze River Economic Belt, and show obvious echelon characteristics

Figure 3: Distribution of the number of drug clinical trials in China as of July 31, 2022 Source: Flint Creation Industry Data Center

From the perspective of the target indications of pharmaceutical clinical trial products, the indications of chemical drugs are mainly anti-tumor drugs, anti-infective drugs, skin and otorhinolaryngology drugs

In terms of innovative drugs, China's innovative drug market has reached a scale of 100 billion, and the number of innovative drugs approved for listing has grown rapidly in recent years, and commercialization has begun to take shape

In terms of innovative drugs, China's innovative drug market has reached a scale of 100 billion, and the number of innovative drugs approved for listing has grown rapidly in recent years, and commercialization has begun to take shape
.

Table 1: From January 2022 to July 31, 2022, the domestically produced Class 1 innovative drugs were approved

Source: Flint Creates Industrial Data Center

In terms of innovative medical device products, China, as the world's second largest medical device market after the United States, has shown a rapid development trend in recent years, and innovative products have accelerated
.
As of July 31, 2022, China has 97,701 listed Class II and III medical devices, of which Guangdong Province (15,510), Jiangsu Province (15,227), Beijing (8,432), Hunan (7,347), and Zhejiang (7,301) ranked in the top five, followed
by Henan, Shandong, Shanghai, Hubei and other places 。 In terms of special approvals, as of July 31, 2022, China has 590 specially approved medical devices, of which Guangdong Province (113), Beijing (112), Zhejiang Province (106), Shanghai (72), and Jiangsu Province (49) rank in the top five
.

In terms of innovative medical device products, China, as the world's second largest medical device market after the United States, has shown a rapid development trend in recent years, and innovative products have accelerated
.

Figure 4: Distribution of the number of Class II and III medical devices listed in China as of July 31, 2022 Source: Flint Creation Industry Data Center

Source: Flint Creates Industrial Data Center

In terms of business model, the scope of influence of the License-in model continues to expand, and has gradually become the product portfolio strategy
of many pharmaceutical companies.
From the perspective of license-in activities, since 2021, a number of key pharmaceutical enterprises such as Zaiding Pharmaceutical, BeiGene, Genting Xinyao, Hengrui Pharmaceutical, Fosun Pharma, Huadong Pharmaceutical, Innovent Biologics, Beihai Kangcheng, Liantuo Biologics have made up for the shortcomings of the self-research system, accelerated portfolio innovation and enhanced market competitiveness
through License-in.
Judging from the sources authorized by License-in, the United States, Britain, Germany, Denmark, Switzerland, Singapore and other pharmaceutical industry development powers have become the main source.

In terms of business model, the scope of influence of the License-in model continues to expand, and has gradually become the product portfolio strategy
of many pharmaceutical companies.

In terms of patent applications, domestic innovation and research and development have promoted a significant increase in the number of patent applications and authorizations in China, and have performed prominently
in the global biotechnology field.
As of July 31, 2022, the number of invention patents authorized in the domestic pharmaceutical field reached 252104
.
Among them, the number of patents authorized in Jiangsu Province, Beijing Municipality, Guangdong Province and other places exceeds 30,000, and shanghai, Zhejiang, Shandong and other provinces and cities are more than
10,000.
At the same time, according to the research data of the Harvard Kennedy School, China's research output in the field of biotechnology ranks in the world's leading position
.
China has the highest number of biotechnology patents filed annually in the world, with its share increasing from 1% in 2000 to 28% in 2019, while the U.
S.
share fell from 45% to 27%.

In biomedical patents, China's 16% annual growth rate far exceeds the 3%
in the United States.
In terms of cell therapy patents, China's total number of patents and growth rate continue to lead
.

In terms of patent applications, domestic innovation and research and development have promoted a significant increase in the number of patent applications and authorizations in China, and have performed prominently
in the global biotechnology field.

Figure 5: Distribution of the number of invention patents authorized in various provinces and cities in China as of July 31, 2022 Source: Flint Creation Industry Data Center

Source: Flint Creates Industrial Data Center

Fourth, innovative talents

Fourth, innovative talents

The serious shortage of innovative talents in medicine and health professions has become a bottleneck restricting the development of the industry, and key cities are actively exploring talent introduction and training and gathering momentum for
innovation and development.

The serious shortage of innovative talents in medicine and health professions has become a bottleneck restricting the development of the industry, and key cities are actively exploring talent introduction and training and gathering momentum for
innovation and development.

Talent is the most fundamental driving force
to promote the development of the medical and health industry.
At present, the number of people engaged in the research, development, production and operation of the biotechnology industry in China is about 1/4 of the number of people in the biotechnology industry in the United States, which has become a bottleneck
restricting the development of China's biomedical industry.

In recent years, the key development areas of the pharmaceutical and health industry have actively carried out corresponding explorations
in the introduction and agglomeration of talents.
First, strengthen the introduction and training of talents through multiple channels, such as the implementation of the introduction plan for talents in key industries in Beijing and Hangzhou; The second is to provide hierarchical monetary subsidies for the introduction of high-end talents, but also to give preferential treatment to talents such as settlement, children's education, household registration application, medical care and other living facilities, such as Suzhou City and Xuzhou City; The third is to build an industry-university-research platform/shared service platform integrating scientific research, industry, talents and resources, and promote the accelerated circulation of talent elements, such as the joint construction of the "Sichuan-Chongqing Science and Technology Resource Sharing Service Platform" in Sichuan-Chongqing region to achieve the open sharing of information resources in the scientific and technological expert database of the two places, open up the docking channel between technical needs and expert services, and promote the interconnection and interconnection of the docking platform for the transfer and transformation of scientific and technological achievements between the two places
.

The national high-level talents in the field of medicine and health are mainly concentrated in the Bohai Rim and the Yangtze River Delta region, and the national industrial talent structure needs to be optimized
urgently.
According to the data of the Flint Industry Data Center, China currently has 8558 national-level high-level people in the field of medicine and
health.
Among them, Beijing (2002), Shanghai (1145), Jiangsu Province (672), Guangdong Province (573), and Zhejiang Province (554) ranked in the top five
.
With the gradual transformation of China's pharmaceutical innovation model from "copying to China" (C2C, Copy to China) to "innovation from China" (IFC, Innovation from China), China urgently needs to strengthen the optimization
of the talent structure of the pharmaceutical industry in key provinces and cities.

The national high-level talents in the field of medicine and health are mainly concentrated in the Bohai Rim and the Yangtze River Delta region, and the national industrial talent structure needs to be optimized
urgently.

Figure 6: Distribution of national high-level talents in the field of medicine and health as of July 31, 2022 Source: Flint Creation Industry Data Center

Source: Flint Creates Industrial Data Center